{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:45:47Z","timestamp":1790484347064,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s12020-020-02277-6","type":"journal-article","created":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T06:16:53Z","timestamp":1585721813000},"page":"204-211","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Morphometric vertebral fractures in patients with castration-resistant prostate cancer undergoing treatment with radium-223: a longitudinal study in the real-life clinical practice"],"prefix":"10.1007","volume":"69","author":[{"given":"Gherardo","family":"Mazziotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Rodari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizia","family":"Gelardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Tosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo A.","family":"Zucali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Pepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Chiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,1]]},"reference":[{"issue":"6","key":"2277_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J. Clin. 68(6), 394\u2013424 (2018). https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA: Cancer J. Clin."},{"issue":"20 Pt 2","key":"2277_CR2","doi-asserted-by":"publisher","first-page":"S6243","DOI":"10.1158\/1078-0432.Ccr-06-0931","volume":"12","author":"RE Coleman","year":"2006","unstructured":"R.E. Coleman, Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. 12(20 Pt 2), S6243\u2013S6249 (2006). https:\/\/doi.org\/10.1158\/1078-0432.Ccr-06-0931","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"2277_CR3","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/1097-0142(19880101)61:13.0.co;2-y","volume":"61","author":"MS Soloway","year":"1988","unstructured":"M.S. Soloway, S.W. Hardeman, D. Hickey, J. Raymond, B. Todd, S. Soloway, M. Moinuddin, Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61(1), 195\u2013202 (1988). https:\/\/doi.org\/10.1002\/1097-0142(19880101)61:13.0.co;2-y","journal-title":"Cancer"},{"issue":"Suppl 5","key":"2277_CR4","doi-asserted-by":"publisher","first-page":"v69","DOI":"10.1093\/annonc\/mdv222","volume":"26","author":"C Parker","year":"2015","unstructured":"C. Parker, S. Gillessen, A. Heidenreich, A. Horwich, Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 26(Suppl 5), v69\u2013v77 (2015). https:\/\/doi.org\/10.1093\/annonc\/mdv222","journal-title":"Ann. Oncol."},{"issue":"2","key":"2277_CR5","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","volume":"65","author":"A Heidenreich","year":"2014","unstructured":"A. Heidenreich, P.J. Bastian, J. Bellmunt, M. Bolla, S. Joniau, T. van der Kwast, M. Mason, V. Matveev, T. Wiegel, F. Zattoni, N. Mottet, EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol. 65(2), 467\u2013479 (2014). https:\/\/doi.org\/10.1016\/j.eururo.2013.11.002","journal-title":"Eur. Urol."},{"issue":"12","key":"2277_CR6","doi-asserted-by":"publisher","first-page":"4451","DOI":"10.1158\/1078-0432.Ccr-04-2244","volume":"11","author":"S Nilsson","year":"2005","unstructured":"S. Nilsson, R.H. Larsen, S.D. Fossa, L. Balteskard, K.W. Borch, J.E. Westlin, G. Salberg, O.S. Bruland, First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin. Cancer Res. 11(12), 4451\u20134459 (2005). https:\/\/doi.org\/10.1158\/1078-0432.Ccr-04-2244","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"2277_CR7","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.ejca.2011.12.023","volume":"48","author":"S Nilsson","year":"2012","unstructured":"S. Nilsson, P. Strang, A.K. Aksnes, L. Franzen, P. Olivier, A. Pecking, J. Staffurth, S. Vasanthan, C. Andersson, O.S. Bruland, A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur. J. Cancer 48(5), 678\u2013686 (2012). https:\/\/doi.org\/10.1016\/j.ejca.2011.12.023","journal-title":"Eur. J. Cancer"},{"issue":"20 Pt 2","key":"2277_CR8","doi-asserted-by":"publisher","first-page":"6250s","DOI":"10.1158\/1078-0432.Ccr-06-0841","volume":"12","author":"OS Bruland","year":"2006","unstructured":"O.S. Bruland, S. Nilsson, D.R. Fisher, R.H. Larsen, High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin. Cancer Res. 12(20 Pt 2), 6250s\u20136257s (2006). https:\/\/doi.org\/10.1158\/1078-0432.Ccr-06-0841","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"2277_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"C. Parker, S. Nilsson, D. Heinrich, S.I. Helle, J.M. O\u2019Sullivan, S.D. Fossa, A. Chodacki, P. Wiechno, J. Logue, M. Seke, A. Widmark, D.C. Johannessen, P. Hoskin, D. Bottomley, N.D. James, A. Solberg, I. Syndikus, J. Kliment, S. Wedel, S. Boehmer, M. Dall\u2019Oglio, L. Franzen, R. Coleman, N.J. Vogelzang, C.G. O\u2019Bryan-Tear, K. Staudacher, J. Garcia-Vargas, M. Shan, O.S. Bruland, O. Sartor, Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369(3), 213\u2013223 (2013). https:\/\/doi.org\/10.1056\/NEJMoa1213755","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"2277_CR10","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/s1470-2045(14)70183-4","volume":"15","author":"O Sartor","year":"2014","unstructured":"O. Sartor, R. Coleman, S. Nilsson, D. Heinrich, S.I. Helle, J.M. O\u2019Sullivan, S.D. Fossa, A. Chodacki, P. Wiechno, J. Logue, A. Widmark, D.C. Johannessen, P. Hoskin, N.D. James, A. Solberg, I. Syndikus, N.J. Vogelzang, C.G. O\u2019Bryan-Tear, M. Shan, O.S. Bruland, C. Parker, Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 15(7), 738\u2013746 (2014). https:\/\/doi.org\/10.1016\/s1470-2045(14)70183-4","journal-title":"Lancet Oncol."},{"issue":"5","key":"2277_CR11","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1093\/annonc\/mdw065","volume":"27","author":"S Nilsson","year":"2016","unstructured":"S. Nilsson, P. Cislo, O. Sartor, N.J. Vogelzang, R.E. Coleman, J.M. O\u2019Sullivan, J. Reuning-Scherer, M. Shan, L. Zhan, C. Parker, Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Ann. Oncol. 27(5), 868\u2013874 (2016). https:\/\/doi.org\/10.1093\/annonc\/mdw065","journal-title":"Ann. Oncol."},{"issue":"5","key":"2277_CR12","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1007\/s00259-017-3900-4","volume":"45","author":"TD Poeppel","year":"2018","unstructured":"T.D. Poeppel, D. Handkiewicz-Junak, M. Andreeff, A. Becherer, A. Bockisch, E. Fricke, L. Geworski, A. Heinzel, B.J. Krause, T. Krause, M. Mitterhauser, W. Sonnenschein, L. Bodei, R.C. Delgado-Bolton, M. Gabriel, EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer. Eur. J. Nuclear Med. Mol. Imaging 45(5), 824\u2013845 (2018). https:\/\/doi.org\/10.1007\/s00259-017-3900-4","journal-title":"Eur. J. Nuclear Med. Mol. Imaging"},{"issue":"2","key":"2277_CR13","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"C.J. Ryan, M.R. Smith, J.S. de Bono, A. Molina, C.J. Logothetis, P. de Souza, K. Fizazi, P. Mainwaring, J.M. Piulats, S. Ng, J. Carles, P.F. Mulders, E. Basch, E.J. Small, F. Saad, D. Schrijvers, H. Van Poppel, S.D. Mukherjee, H. Suttmann, W.R. Gerritsen, T.W. Flaig, D.J. George, E.Y. Yu, E. Efstathiou, A. Pantuck, E. Winquist, C.S. Higano, M.E. Taplin, Y. Park, T. Kheoh, T. Griffin, H.I. Scher, D.E. Rathkopf, Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368(2), 138\u2013148 (2013). https:\/\/doi.org\/10.1056\/NEJMoa1209096","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"2277_CR14","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/s1470-2045(18)30860-x","volume":"20","author":"M Smith","year":"2019","unstructured":"M. Smith, C. Parker, F. Saad, K. Miller, B. Tombal, Q.S. Ng, M. Boegemann, V. Matveev, J.M. Piulats, L.E. Zucca, O. Karyakin, G. Kimura, N. Matsubara, W.C. Nahas, F. Nole, E. Rosenbaum, A. Heidenreich, Y. Kakehi, A. Zhang, H. Krissel, M. Teufel, J. Shen, V. Wagner, C. Higano, Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20(3), 408\u2013419 (2019). https:\/\/doi.org\/10.1016\/s1470-2045(18)30860-x","journal-title":"Lancet Oncol."},{"issue":"6","key":"2277_CR15","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.eururo.2019.01.026","volume":"75","author":"A Dalla Volta","year":"2019","unstructured":"A. Dalla Volta, A.M. Formenti, A. Berruti, Higher risk of fragility fractures in prostate cancer patients treated with combined radium-223 and abiraterone: prednisone may be the culprit. Eur. Urol. 75(6), 894\u2013895 (2019). https:\/\/doi.org\/10.1016\/j.eururo.2019.01.026","journal-title":"Eur. Urol."},{"issue":"10","key":"2277_CR16","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.amjmed.2010.02.028","volume":"123","author":"G Mazziotti","year":"2010","unstructured":"G. Mazziotti, E. Canalis, A. Giustina, Drug-induced osteoporosis: mechanisms and clinical implications. Am. J. Med. 123(10), 877\u2013884 (2010). https:\/\/doi.org\/10.1016\/j.amjmed.2010.02.028","journal-title":"Am. J. Med."},{"issue":"5","key":"2277_CR17","doi-asserted-by":"publisher","first-page":"R231","DOI":"10.1530\/eje-17-0154","volume":"177","author":"G Mazziotti","year":"2017","unstructured":"G. Mazziotti, A.M. Formenti, S. Frara, E. Roca, P. Mortini, A. Berruti, A. Giustina, Management of endocrine disease: risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects. Eur. J. Endocrinol 177(5), R231\u2013R248 (2017). https:\/\/doi.org\/10.1530\/eje-17-0154","journal-title":"Eur. J. Endocrinol"},{"issue":"1","key":"2277_CR18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3892\/mco.2019.1852","volume":"11","author":"EL Rizzini","year":"2019","unstructured":"E.L. Rizzini, P. Ghedini, R. Cardano, C. Bellarosa, A.G. Morganti, S. Fanti, F: Monari, Importance of the correct assessment of bone fractures in the clinical management of metastatic castration-resistant prostate cancer treated with radium-223: a case report. Mol. Clin. Oncol. 11(1), 63\u201366 (2019). https:\/\/doi.org\/10.3892\/mco.2019.1852","journal-title":"Mol. Clin. Oncol."},{"issue":"Suppl 3","key":"2277_CR19","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1007\/s00198-002-1348-1","volume":"14","author":"HK Genant","year":"2003","unstructured":"H.K. Genant, M. Jergas, Assessment of prevalent and incident vertebral fractures in osteoporosis research. Osteoporos. Int. 14(Suppl 3), S43\u2013S55 (2003). https:\/\/doi.org\/10.1007\/s00198-002-1348-1","journal-title":"Osteoporos. Int."},{"issue":"2","key":"2277_CR20","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/jbmr.5650070214","volume":"7","author":"C Cooper","year":"1992","unstructured":"C. Cooper, E.J. Atkinson, W.M. O\u2019Fallon, L.J. Melton 3rd, Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985\u20131989. J. Bone Miner. Res. 7(2), 221\u2013227 (1992). https:\/\/doi.org\/10.1002\/jbmr.5650070214","journal-title":"J. Bone Miner. Res."},{"issue":"7","key":"2277_CR21","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1359\/jbmr.2003.18.7.1254","volume":"18","author":"T Jalava","year":"2003","unstructured":"T. Jalava, S. Sarna, L. Pylkkanen, B. Mawer, J.A. Kanis, P. Selby, M. Davies, J. Adams, R.M. Francis, J. Robinson, E. McCloskey, Association between vertebral fracture and increased mortality in osteoporotic patients. J. Bone Miner. Res. 18(7), 1254\u20131260 (2003). https:\/\/doi.org\/10.1359\/jbmr.2003.18.7.1254","journal-title":"J. Bone Miner. Res."},{"issue":"9","key":"2277_CR22","doi-asserted-by":"publisher","first-page":"806","DOI":"10.4065\/mcp.2010.0082","volume":"85","author":"JD Adachi","year":"2010","unstructured":"J.D. Adachi, S. Adami, S. Gehlbach, F.A. Anderson Jr., S. Boonen, R.D. Chapurlat, J.E. Compston, C. Cooper, P. Delmas, A. Diez-Perez, S.L. Greenspan, F.H. Hooven, A.Z. LaCroix, R. Lindsay, J.C. Netelenbos, O. Wu, J. Pfeilschifter, C. Roux, K.G. Saag, P.N. Sambrook, S. Silverman, E.S. Siris, G. Nika, N.B. Watts, Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women. Mayo Clin. Proc. 85(9), 806\u2013813 (2010). https:\/\/doi.org\/10.4065\/mcp.2010.0082","journal-title":"Mayo Clin. Proc."},{"issue":"3","key":"2277_CR23","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s00198-004-1691-5","volume":"16","author":"R Lindsay","year":"2005","unstructured":"R. Lindsay, S. Pack, Z. Li, Longitudinal progression of fracture prevalence through a population of postmenopausal women with osteoporosis. Osteoporos. Int. 16(3), 306\u2013312 (2005). https:\/\/doi.org\/10.1007\/s00198-004-1691-5","journal-title":"Osteoporos. Int."},{"issue":"3","key":"2277_CR24","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s00198-011-1774-z","volume":"23","author":"YM Kim","year":"2012","unstructured":"Y.M. Kim, S. Demissie, H.K. Genant, X. Cheng, W. Yu, E.J. Samelson, D.P. Kiel, M.L. Bouxsein, Identification of prevalent vertebral fractures using CT lateral scout views: a comparison of semi-automated quantitative vertebral morphometry and radiologist semi-quantitative grading. Osteoporos. Int. 23(3), 1007\u20131016 (2012). https:\/\/doi.org\/10.1007\/s00198-011-1774-z","journal-title":"Osteoporos. Int."},{"key":"2277_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.7150\/jca.1.80","volume":"1","author":"CM Costelloe","year":"2010","unstructured":"C.M. Costelloe, H.H. Chuang, J.E. Madewell, N.T. Ueno, Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST. J. Cancer 1, 80\u201392 (2010). https:\/\/doi.org\/10.7150\/jca.1.80","journal-title":"J. Cancer"},{"issue":"7","key":"2277_CR26","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/jbmr.5650110716","volume":"11","author":"HK Genant","year":"1996","unstructured":"H.K. Genant, M. Jergas, L. Palermo, M. Nevitt, R.S. Valentin, D. Black, S.R. Cummings, Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group. J. Bone Miner. Res. 11(7), 984\u2013996 (1996). https:\/\/doi.org\/10.1002\/jbmr.5650110716","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"2277_CR27","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.3892\/ol.2018.9785","volume":"17","author":"A Prelaj","year":"2019","unstructured":"A. Prelaj, S.E. Rebuzzi, F. Buzzacchino, C. Pozzi, C. Ferrara, V. Frantellizzi, G.A. Follacchio, L. Civitelli, G. De Vincentis, S. Tomao, V. Bianco, Radium-223 in patients with metastatic castration-resistant prostate cancer: Efficacy and safety in clinical practice. Oncol. Lett. 17(2), 1467\u20131476 (2019). https:\/\/doi.org\/10.3892\/ol.2018.9785","journal-title":"Oncol. Lett."},{"issue":"2","key":"2277_CR28","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s13139-014-0314-0","volume":"49","author":"KS Miyazaki","year":"2015","unstructured":"K.S. Miyazaki, Y. Kuang, S.A. Kwee, Changes in skeletal tumor activity on (18)F-choline PET\/CT in patients receiving (223) radium radionuclide therapy for metastatic prostate cancer. Nucl. Med Mol. Imaging 49(2), 160\u2013164 (2015). https:\/\/doi.org\/10.1007\/s13139-014-0314-0","journal-title":"Nucl. Med Mol. Imaging"},{"issue":"1","key":"2277_CR29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.5301\/uro.5000206","volume":"84","author":"P Scalzi","year":"2017","unstructured":"P. Scalzi, C. Baiocco, S. Genovese, A. Trevisan, Z. Sirotova, C. Poti, Evaluation of bone metastases by 18F-choline PET\/CT in a patient with castration-resistant prostate cancer treated with radium-223. Urologia 84(1), 61\u201364 (2017). https:\/\/doi.org\/10.5301\/uro.5000206","journal-title":"Urologia"},{"issue":"3","key":"2277_CR30","doi-asserted-by":"publisher","first-page":"289","DOI":"10.18926\/amo\/56075","volume":"72","author":"K Kitajima","year":"2018","unstructured":"K. Kitajima, S. Yamamoto, S. Odawara, K. Kobayashi, M. Fujiwara, N. Kamikonya, K. Fukushima, Y. Nakanishi, T. Hashimoto, Y. Yamada, T. Suzuki, A. Kanematsu, M. Nojima, K. Yamakado, Diagnostic performance of 11C-choline PET\/CT and FDG PET\/CT in prostate cancer. Acta Med. Okayama 72(3), 289\u2013296 (2018). https:\/\/doi.org\/10.18926\/amo\/56075","journal-title":"Acta Med. Okayama"},{"issue":"12","key":"2277_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw180","volume":"30","author":"S Gillessen","year":"2019","unstructured":"S. Gillessen, A. Omlin, G. Attard, J.S. de Bono, E. Efstathiou, K. Fizazi, S. Halabi, P.S. Nelson, O. Sartor, M.R. Smith, H.R. Soule, H. Akaza, T.M. Beer, H. Beltran, A.M. Chinnaiyan, G. Daugaard, I.D. Davis, M. De Santis, C.G. Drake, R.A. Eeles, S. Fanti, M.E. Gleave, A. Heidenreich, M. Hussain, N.D. James, F.E. Lecouvet, C.J. Logothetis, K. Mastris, S. Nilsson, W.K. Oh, D. Olmos, A.R. Padhani, C. Parker, M.A. Rubin, J.A. Schalken, H.I. Scher, A. Sella, N.D. Shore, E.J. Small, C.N. Sternberg, H. Suzuki, C.J. Sweeney, I.F. Tannock, B. Tombal, Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann. Oncol. 30(12), e3 (2019). https:\/\/doi.org\/10.1093\/annonc\/mdw180","journal-title":"Ann. Oncol."},{"key":"2277_CR32","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1210\/jc.2011-2189","volume":"97","author":"G Attard","year":"2012","unstructured":"G. Attard, A. Reid, R. Auchus, B. Hughes, A. Cassidy, E. Thompson, N. Oommen, E. Folkered, M. Dowsett, W. Arlt, Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J. Clin. Endocrinol. Metab. 97, 507\u2013516 (2012). https:\/\/doi.org\/10.1210\/jc.2011-2189","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2277_CR33","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1530\/eje-12-0865","volume":"168","author":"H Falhammar","year":"2013","unstructured":"H. Falhammar, H. Filipsson Nystr\u00f6m, A. Wedell, K. Brismar, M. Thor\u00e9n, Bone mineral density, bone markers, and fractures in adult males with congenital adrenal hyperplasia. Eur. J. Endocrinol. 168, 331\u2013341 (2013). https:\/\/doi.org\/10.1530\/eje-12-0865","journal-title":"Eur. J. Endocrinol."},{"key":"2277_CR34","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.1210\/jc.2007-0744","volume":"92","author":"H Falhammar","year":"2007","unstructured":"H. Falhammar, H. Filipsson, G. Holmdahl, P. Janson, A. Nordenskj\u00f6ld, K. Hagenfeldt, M. Thor\u00e9n, Fractures and bone mineral density in adult women with 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 92, 4643\u20134649 (2007). https:\/\/doi.org\/10.1210\/jc.2007-0744","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2277_CR35","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1210\/jc.2011-2036","volume":"97","author":"K Koetz","year":"2012","unstructured":"K. Koetz, M. Ventz, S. Diederich, M. Quinkler, Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy. J. Clin. Endocrinol. Metab. 97, 85\u201392 (2012). https:\/\/doi.org\/10.1210\/jc.2011-2036","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"2277_CR36","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/jbmr.3595","volume":"34","author":"RL Prince","year":"2019","unstructured":"R.L. Prince, J.R. Lewis, W.H. Lim, G. Wong, K.E. Wilson, B.C. Khoo, K. Zhu, D.P. Kiel, J.T. Schousboe, Adding lateral spine imaging for vertebral fractures to densitometric screening: improving ascertainment of patients at high risk of incident osteoporotic fractures. J. Bone Miner. Res. 34(2), 282\u2013289 (2019). https:\/\/doi.org\/10.1002\/jbmr.3595","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"2277_CR37","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1210\/er.2018-00005","volume":"39","author":"G Mazziotti","year":"2018","unstructured":"G. Mazziotti, S. Frara, A. Giustina, Pituitary diseases and bone. Endocr. Rev. 39(4), 440\u2013488 (2018). https:\/\/doi.org\/10.1210\/er.2018-00005","journal-title":"Endocr. Rev."},{"issue":"1","key":"2277_CR38","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00198-006-0199-6","volume":"18","author":"HK Genant","year":"2007","unstructured":"H.K. Genant, P.D. Delmas, P. Chen, Y. Jiang, E.F. Eriksen, G.P. Dalsky, R. Marcus, J. San Martin, Severity of vertebral fracture reflects deterioration of bone microarchitecture. Osteoporos. Int. 18(1), 69\u201376 (2007). https:\/\/doi.org\/10.1007\/s00198-006-0199-6","journal-title":"Osteoporos. Int."},{"issue":"1","key":"2277_CR39","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00198-013-2460-0","volume":"25","author":"H Johansson","year":"2014","unstructured":"H. Johansson, A. Oden, E.V. McCloskey, J.A. Kanis, Mild morphometric vertebral fractures predict vertebral fractures but not non-vertebral fractures. Osteoporos. Int.25(1), 235\u2013241 (2014). https:\/\/doi.org\/10.1007\/s00198-013-2460-0","journal-title":"Osteoporos. Int."},{"issue":"1","key":"2277_CR40","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12020-015-0738-z","volume":"52","author":"G Mazziotti","year":"2016","unstructured":"G. Mazziotti, M. Doga, S. Frara, F. Maffezzoni, T. Porcelli, L. Cerri, R. Maroldi, A. Giustina, Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency. Endocrine 52(1), 103\u2013110 (2016). https:\/\/doi.org\/10.1007\/s12020-015-0738-z","journal-title":"Endocrine"},{"issue":"5","key":"2277_CR41","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.euo.2018.11.001","volume":"2","author":"JS Joseph","year":"2019","unstructured":"J.S. Joseph, V. Lam, M.I. Patel, Preventing osteoporosis in men taking androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Eur. Urol. Oncol. 2(5), 551\u2013561 (2019). https:\/\/doi.org\/10.1016\/j.euo.2018.11.001","journal-title":"Eur. Urol. Oncol."},{"key":"2277_CR42","doi-asserted-by":"publisher","first-page":"100114","DOI":"10.1016\/j.ctarc.2018.100114","volume":"18","author":"KK Yap","year":"2019","unstructured":"K.K. Yap, W. Wong, L. Ji, S. Groshen, D.I. Quinn, A.H. Bryce, T.B. Dorff, Impact of timing of administration of bone supportive therapy on pain palliation from radium-223. Cancer Treat. Res. Commun. 18, 100114 (2019). https:\/\/doi.org\/10.1016\/j.ctarc.2018.100114","journal-title":"Cancer Treat. Res. Commun."},{"issue":"5","key":"2277_CR43","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1093\/annonc\/mdx044","volume":"28","author":"O Sartor","year":"2017","unstructured":"O. Sartor, R.E. Coleman, S. Nilsson, D. Heinrich, S.I. Helle, J.M. O\u2019Sullivan, N.J. Vogelzang, O. Bruland, S. Kobina, S. Wilhelm, L. Xu, M. Shan, M.W. Kattan, C. Parker, An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. Ann. Oncol. 28(5), 1090\u20131097 (2017). https:\/\/doi.org\/10.1093\/annonc\/mdx044","journal-title":"Ann. Oncol."},{"issue":"3","key":"2277_CR44","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.jocd.2011.05.003","volume":"14","author":"S Sullivan","year":"2011","unstructured":"S. Sullivan, J. Wagner, N.M. Resnick, J. Nelson, S.K. Perera, S.L. Greenspan, Vertebral fractures and the misclassification of osteoporosis in men with prostate cancer. J. Clin. Densitom. 14(3), 348\u2013353 (2011). https:\/\/doi.org\/10.1016\/j.jocd.2011.05.003","journal-title":"J. Clin. Densitom."},{"key":"2277_CR45","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.bone.2017.04.008","volume":"101","author":"BJ Schwaiger","year":"2017","unstructured":"B.J. Schwaiger, D.L. Kopperdahl, L. Nardo, L. Facchetti, A.S. Gersing, J. Neumann, K.J. Lee, T.M. Keaveny, T.M. Link, Vertebral and femoral bone mineral density and bone strength in prostate cancer patients assessed in phantomless PET\/CT examinations. Bone 101, 62\u201369 (2017). https:\/\/doi.org\/10.1016\/j.bone.2017.04.008","journal-title":"Bone"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-020-02277-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-020-02277-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-020-02277-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T23:44:29Z","timestamp":1617234269000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-020-02277-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,1]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["2277"],"URL":"https:\/\/doi.org\/10.1007\/s12020-020-02277-6","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,1]]},"assertion":[{"value":"13 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"G.M. was consultant for Ipsen and Eli Lilly. A.C. received speaker honoraria from General Electric and Sirtex Medical System, acted as scientific advisor to Blue Earth Diagnostics and Advanced Accelerator Applications, and benefited from an unconditional grant from Sanofi to Humanitas University. All honoraria are outside the scope of the submitted work. All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}